Antibodies against monocyte chemotactic proteins

57-75. (canceled)

A method of treating a subject suffering from a disorder selected from the group consisting of glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody heavy chain, wherein said antibody heavy chain comprises a variable region complementarity determining region (CDR) from an antibody heavy chain variable region set forth in SEQ ID NO:27.

A method of treating a subject suffering from a disorder selected from the group consisting of glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody light chain, wherein said antibody light chain comprises a variable region complementarity determining region (CDR) from an antibody light chain variable region as set forth in SEQ ID NO:28.

A method of treating a subject suffering from a disorder selected from the group consisting of glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof comprises a variable heavy chain region as set forth in SEQ ID NO:27 and a variable light chain region as set forth in SEQ ID NO:28

A method of treating a subject suffering from a disorder selected from the group consisting of glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprises MCP-1 and at least one other β-chemokine, wherein said antibody or antigen-binding fragment thereof comprises a variable region complementarity determining region (CDR) from a heavy chain variable region set forth in SEQ ID NO:27.

A method of treating a subject suffering from a disorder selected from the group consisting of glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprises MCP-1 and at least one other β-chemokine, wherein said antibody or antigen-binding fragment thereof comprises a variable region complementarity determining region (CDR) from a light chain variable region set forth in SEQ ID NO:28.

A method of treating a subject suffering from a disorder selected from the group consisting of glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated single-chain antibody antigen-binding fragment, wherein said single-chain antibody antigen-binding fragment specifically binds MCP-1 and at least one other monocyte chemotactic protein, wherein said single-chain antibody antigen-binding fragment comprises a heavy chain variable region complementarity determining region (CDR) from an antibody heavy chain variable region set forth in SEQ ID NO:27 or a light chain variable region complementarity determining region (CDR) from an antibody light chain variable region set forth in SEQ ID NO:28, wherein said antibody fragment does not have agonistic activity for MCP-2.